



Contents lists available at ScienceDirect

## Seminars in Arthritis and Rheumatism

journal homepage: [www.elsevier.com/locate/semarthrit](http://www.elsevier.com/locate/semarthrit)

## The effects of sprifermin on symptoms and structure in a subgroup at risk of progression in the FORWARD knee osteoarthritis trial

Hans Guehring<sup>a</sup>, Flavie Moreau<sup>b,1</sup>, Benjamin Daelken<sup>a</sup>, Christoph Ladell<sup>a,2</sup>, Oliver Guenther<sup>a</sup>, Asger Reinstrup Bihlet<sup>c</sup>, Wolfgang Wirth<sup>d,e,f</sup>, Felix Eckstein<sup>d,e,f</sup>, Marc Hochberg<sup>g</sup>, Philip G. Conaghan<sup>h,\*</sup>

<sup>a</sup> Merck KGaA, Darmstadt, Germany

<sup>b</sup> EMD Serono Research and Development Institute, Inc., Billerica, MA, USA

<sup>c</sup> NBCD A/S, Herlev, Denmark

<sup>d</sup> Chondrometrics GmbH, Ainning, Germany

<sup>e</sup> Department of Imaging and Functional Musculoskeletal Research, Institute of Anatomy & Cell Biology, Paracelsus Medical University Salzburg & Nuremberg, Salzburg, Austria

<sup>f</sup> Ludwig Boltzmann Institute for Arthritis and Rehabilitation, Paracelsus Medical University, Salzburg, Austria

<sup>g</sup> University of Maryland School of Medicine, Baltimore, MD, USA

<sup>h</sup> Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Chapel Allerton Hospital, Leeds, UK

## ARTICLE INFO

## Keywords:

Knee osteoarthritis  
Magnetic resonance imaging  
Osteoarthritis  
Pain  
Treatment

## ABSTRACT

**Objective:** To assess pain outcomes and cartilage thickness change in a subgroup at risk (SAR) of further progression in the FORWARD trial of knee osteoarthritis patients treated with sprifermin.

**Methods:** Patients were randomised 1:1:1:1 to: sprifermin 100 µg every 6 months (q6mo), 100 µg q12mo, 30 µg q6mo, 30 µg q12mo, or placebo for 18 months. SAR was defined as baseline medial or lateral minimum joint-space width (mJSW) 1.5–3.5 mm and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain score 40–90 units. Follow-up to 3 years was included in the analysis. Treatment benefit was explored by repeated measures, linear dose-effect trends by timepoint.

**Results:** The SAR comprised 161 (29%) of 549 patients. Mean difference (95% CI) in WOMAC pain at year 3 for sprifermin 100 µg q6mo vs placebo SAR was -8.75 (-22.42, 4.92) for SAR vs 0.97 (-6.22, 8.16) for the intent-to-treat population. SAR placebo patients lost more cartilage over 2 years than the modified ITT (mITT) placebo arm (mean change from baseline, mm [SD]: -0.05 [0.10] vs -0.02 [0.07]). Net total femorotibial joint thickness gain with sprifermin 100 µg q6mo (adjusted mean difference from placebo [95% CI] was similar in the SAR and in the mITT group: 0.06 [0.01, 0.11] vs 0.05 [0.03, 0.07]).

**Conclusions:** Selection for low mJSW and moderate-to-high pain at baseline resulted in more rapid disease progression and demonstrated translation of structure modification (with maintained net benefit on total cartilage thickness) into symptomatic benefit. This subgroup may represent a target population for future trials.

**Clinical trial registration:** : NCT01919164.

© 2021 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>)

## Introduction

Osteoarthritis (OA) is a prevalent disease associated with pain, reduced joint function, diminished quality of life, and a substantial healthcare burden [1,2]. OA is characterised by structural alterations, particularly progressive loss of articular cartilage [1]. Current OA drugs

alleviate symptoms but do not prevent structural disease progression [2,3]. Most symptom-targeting agents have short-term benefits [4] and substantial safety considerations [5]. There is, therefore, an unmet need for disease-modifying OA drugs (DMOADs) that offer structural improvements and consequent symptomatic benefit in pain or function [6–8].

Sprifermin is a recombinant human fibroblast growth factor 18 investigated as a possible anabolic intra-articular (i.a.) DMOAD. Pre-clinical studies indicate that the mode of action of sprifermin is to stimulate chondrocytes and hyaline extracellular matrix synthesis [9–12]. The phase II FORWARD trial demonstrated differences in longitudinal cartilage thickness change with sprifermin versus placebo

\* Corresponding author.

E-mail address: [P.Conaghan@leeds.ac.uk](mailto:P.Conaghan@leeds.ac.uk) (P.G. Conaghan).

<sup>1</sup> An affiliate of Merck KGaA, Darmstadt, Germany.

<sup>2</sup> Current affiliation: BioBone BV, Amsterdam, Netherlands.

in people with symptomatic radiographic knee OA; [13] at Year 2 and 3, significant dose-dependent effects on total femorotibial joint (TFTJ) cartilage thickness (primary endpoint) were demonstrated. Two- and 3-year improvements in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scores and sub-scale scores were seen in all treatment groups [13].

Recent literature supports selection of patients with moderate–high WOMAC scores and low joint space width to improve detection of a pain response while enriching for structural progression [14–17]. Such patients display greater cartilage loss than those without joint space narrowing [18,19] and low pain frequency [20].

Insights from FORWARD suggest a floor effect due to the relatively high proportion of patients with low pain (32% with WOMAC pain sub-scale score <40/100) and relatively high minimum joint space width (mJSW; 50% >3.7 mm) at baseline.

The post-hoc analysis described herein tested the hypothesis that selection of a more homogenous OA patient subgroup from FORWARD (subgroup at risk [SAR]) would show symptomatic benefit over placebo in addition to structural modification. Sensitivity analyses explored whether a mJSW- and pain-defined subgroup would better differentiate from the intention-to-treat (ITT)/modified ITT (mITT) cohort than a definition based on either mJSW or pain alone.

## Methods

### Study design

FORWARD was a multicentre, randomised, double-blind, placebo-controlled, dose-finding, phase II, 5-year trial (NCT01919164). Details of the methods have been reported [13]. Briefly, patients aged 40–85 with symptomatic radiographic knee OA, Kellgren–Lawrence (KL) grade 2 or 3, and medial mJSW  $\geq 2.5$  mm in the target knee were randomised (1:1:1:1:1) to receive three once-weekly i.a. injections of: 30  $\mu\text{g}$  sprifermin every 6 months (q6mo) or q12mo; 100  $\mu\text{g}$  sprifermin q6mo or q12mo; or placebo for 18 months (Fig. 1). The primary endpoint was change in TFTJ cartilage thickness from baseline to 2 years. Total WOMAC and pain subscale scores were secondary endpoints. At the time of this analysis, data from the 2-year treatment period plus 1 year of follow-up (at Year 3) were available.

The ITT population (all randomised patients) was used for WOMAC pain analyses; the mITT population (all ITT patients with one baseline and  $\geq 1$  post-treatment qMRI assessment) was used for qMRI efficacy analyses; the safety analysis population included all patients who received  $\geq 1$  dose of treatment. All patients gave written informed consent. The study was performed in accordance with the Declaration of Helsinki.

### Patient SAR

The baseline variables for selecting a subgroup that may potentially benefit in terms of pain and structure modification were mJSW and WOMAC pain [14–18,21].

Based on published measurements for different mJSW strata [17,22,23], mJSW limits of 1.5–3.5 mm (minimum measured medially or laterally, since FORWARD included patients with both medial and lateral compartment disease) were selected.

WOMAC pain score selection of 40–90 was consistent with established study practice [21]. Sub-question A1, referring to pain on walking, was the only protocol-specified pain score (used at screening only, but not at baseline). The current analysis evaluated consistency of treatment effect across all pain endpoints.

Therefore, the subgroup formalised as a post-hoc analysis of a SAR was defined as mJSW >1.5 to  $\leq 3.5$  mm, and WOMAC scores of 40–90.

A 'non-SAR' subgroup from the remainder of the ITT population included patients with mJSW >1.5 mm who did not meet the SAR

WOMAC criteria and patients with mJSW >3.5 mm, regardless of WOMAC pain score. Patients with mJSW <1.5 mm, missing mJSW or WOMAC data were excluded.

### Outcomes

TFTJ cartilage thickness was assessed by qMRI at baseline, before the first injection of each cycle (6, 12 and 18 months) and at follow-up visits (24 and 36 months), using 1.5 or 3 Tesla clinical MRI scanners [13]. Pain was self-assessed as part of the 24-question WOMAC questionnaire [13].

Key structural secondary endpoints included change from baseline in TFTJ cartilage thickness at Year 3 and versus placebo. Key pain secondary endpoints included change from baseline to Year 3 in WOMAC sub-scores for the SAR, non-SAR subgroup, and ITT population, difference in WOMAC sub-score versus placebo in the SAR, and subgroups of patients with different baseline characteristics, as well as percentage of patients with pain improvement scores  $\geq 10$  points from baseline over 3 years. Clinically relevant individual improvements in WOMAC pain have been described as  $\geq 10$  points from baseline [24]. Also reported were patient-reported outcomes (PROs) at Year 3 with sprifermin 100  $\mu\text{g}$  q6mo versus placebo in the SAR.

Differentiation of responses were evaluated by mJSW and pain individually and together.

Safety, including adverse events (AEs) and serious AEs (SAEs), was assessed up to 3 years.

Statistical analyses are described in the Supplement.

## Results

### Patients

The ITT population comprised 549 patients, of whom 161 (29%) were classified as the SAR and 339 (62%) as the non-SAR subgroup (Fig. 1). Forty-nine patients (9%) were not classifiable due to missing data ( $n = 46$ ) or having mJSW <1.5 mm at baseline ( $n = 3$ ). The mITT included 494 patients.

SAR baseline characteristics were similar to the ITT population in terms of age, sex, race and body mass index (Table 1). More SAR patients had KL grade 3, a lower median mJSW, and higher median WOMAC pain than the ITT population (table S1).

### WOMAC pain sub-score

WOMAC pain changes from baseline in placebo-treated patients of the SAR were consistent with the ITT population (Fig. 2). At Year 3, the placebo WOMAC pain score response from baseline was approximately a 20-point (SAR) and 24-point (ITT population) decrease (Fig. 2).

Compared with the ITT population, a dose-dependent improvement in WOMAC pain in the SAR was observed with sprifermin, which increased to Year 3 (sprifermin 100  $\mu\text{g}$  q6mo versus placebo,  $p < 0.05$ ; Fig. 2). In the non-SAR subgroup, reduction in pain with placebo at Year 3 was numerically greater versus sprifermin 100  $\mu\text{g}$  q6mo (absolute mean difference: 6.45 points [95% CI – 1.76; 14.66]; Fig. S1). More than 95% of SAR sprifermin-treated patients (100  $\mu\text{g}$  groups) achieved a clinically relevant observed improvement from baseline of  $\geq 10$  in WOMAC pain score at Year 3 (Fig. S2). There was greater differentiation between sprifermin 100  $\mu\text{g}$  q6mo and placebo in WOMAC pain sub-score in the SAR versus either baseline characteristic alone (Fig. 3).

Adjusted mean difference between SAR sprifermin 100  $\mu\text{g}$  q6mo and placebo at Years 2 and 3 were –5.82 (95% CI – 18.87; 7.23) and –8.75 (95% CI – 22.42; 4.92), respectively (Table 2). A sensitivity analysis (unadjusted mean difference in the descriptive results) showed more pronounced differences between sprifermin and placebo. In the




Fig. 1. Study disposition.

\* Reasons for withdrawal: adverse event (17), protocol non-compliance (12), withdrew consent (42), disease progression (3), death (1), other (23).

Table 1

Overall baseline characteristics in the ITT, SAR, and non-SAR populations.

	ITT (n = 549)	SAR (n = 161)	Non-SAR subgroup (n = 339)
Median age, years	65.0	66.0	65.0
Predominantly medial disease, %	68.3	83.5	62.0
Female, %	69.0	78.9	63.4
White race, %	80.0	78.9	79.1
Median BMI, kg/m <sup>2</sup>	28.6	29.6	27.8
KL grade 2, %*	69.0	47.2	78.2
KL grade 3, %*	31.0	52.8	21.8
Median mJSW, mm (min, max)*	3.6 (1.0, 6.6)	2.8 (1.5, 3.5)	4.1 (1.7, 6.6)
Median WOMAC pain (min, max)*	46.0 (10.0, 88.0)	54 (40.0, 86.0)	40.0 (10.0, 88.0)

\* In the target knee. BMI, body mass index; ITT, intention-to-treat; KL, Kellgren-Lawrence; mJSW, minimum joint space width; SAR, subgroup at risk; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index.

ITT population, change from baseline in WOMAC pain was not different between sprifermin 100 µg q6mo and placebo (adjusted mean difference at Year 3: 0.97 [95% CI -6.22;8.16]). The absolute mean change from baseline in WOMAC sub-score at Year 3 in the non-SAR subgroup was 6.45 (95% CI - 1.76;14.66).

#### TFTJ cartilage thickness

SAR placebo-treated patients had numerically greater TFTJ cartilage loss between baseline and 2 years than the mITT population (observed mean loss 0.05 vs 0.02 mm; Fig. 4). A similar difference was observed between the SAR and non-SAR subgroup (Fig. S3). In the SAR and mITT population, a nominally significant dose-dependent effect of sprifermin on observed change in total cartilage thickness was seen from Year 1 (Fig. 4). Increased cartilage thickness with

sprifermin 100 µg q6mo versus placebo at Year 2 was slightly greater in the SAR (adjusted mean difference 0.06 mm [95% CI 0.01;0.11]; Table 3) versus the mITT population (0.05 mm [95% CI 0.02;0.08]).


While mean cartilage thickness decreased in all treatment groups between Years 2 and 3 in both the SAR and mITT population, the mean difference versus placebo at Year 2 remained similar up to Year 3 (Fig. 4). This was also true of the SAR and non-SAR subgroup (Table 3, Fig. S3).

#### Other PROs


Three-year findings for other PROs with sprifermin 100 µg q6mo were consistent with WOMAC pain, including total WOMAC score, WOMAC stiffness and function, total weight bearing, WOMAC pain Q3 and Q4 score, knee pain on numerical rating scale, and patient global assessment score (Fig. S4).

#### Safety

The proportion of patients with AEs with sprifermin versus placebo in the SAR (99.2% vs 100.0%) was comparable to the safety analysis population (96.8% vs 98.1%), as were local AEs (table S2). More placebo-treated patients in the SAR had SAEs versus the safety analysis population (47.1% vs 33.6%) but SAEs were comparable for sprifermin-treated patients in the two groups (21.3% vs 23.6%). The proportion of placebo-treated patients with musculoskeletal and connective tissue disorder SAEs was 29.4% (SAR) and 13.1% (safety analysis population). All SAEs were unrelated to sprifermin. There was one patient death, due to gastric cancer, in the SAR placebo group.



**Fig. 2.** Observed change in WOMAC pain sub-score at Year 3. CI, confidence interval; ITT, intention-to-treat; q6mo, every 6 months; q12mo, every 12 months; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index.



**Fig. 3.** Observed mean difference in change from baseline to Year 3 in WOMAC pain sub-score (95% CI) with sprifermin 100 µg q6mo vs placebo\* for subgroups of patients with different baseline characteristics. \*N = number of participants receiving placebo vs sprifermin 100 µg q6mo. BL, baseline; ITT, intention-to-treat; mJSW, minimum joint space width; q6mo, every 6 months; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index.

**Discussion**

Both structural and symptomatic benefit are needed for an agent to be considered a DMOAD [25], and clinical trials have previously failed to demonstrate concomitant improvements in both

outcomes [7,26–28]. This may be because patient populations were too heterogeneous, typically including patients whose structural degradation and associated pain symptoms may progress at different rates or not at all [7,14,29]. In addition, patients without cartilage loss at baseline may not be expected to benefit

**Table 2**  
Adjusted mean difference in WOMAC pain sub-score with sprifermin 100 µg q6mo (n = 34) vs placebo (n = 33) in the SAR.

	Number of non-missing values (n)		Adjusted* mean difference with sprifermin 100 µg q6mo vs placebo (95% CI) <sup>†</sup>	Trend test <sup>‡</sup>
	Sprifermin 100 µg q6mo	Placebo		
Year 1	31	31	-3.65 (-15.73–8.43)	0.435
Year 1.5	31	28	-4.88 (-17.73–7.97)	0.307
Year 2	31	28	-5.82 (-18.87–7.23)	0.246
Year 3	28	27	-8.75 (-22.42–4.92)	0.037


\* Repeated measure model with adjustment on baseline and pooled country to account for potential baseline difference generated by the creation of the subgroup and missing data.

<sup>†</sup> CIs are adjusted for multiplicity of treatment groups.

<sup>‡</sup> Dose-effect trend test across all treatment groups for adjusted values.

CI, confidence interval; n, number of participants with change from baseline available; q6mo, every 6 months; SAR, subgroup at risk; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index.





**Fig. 4.** Observed change in total femorotibial joint cartilage thickness at Year 3. CI, confidence interval; mITT, modified intention-to-treat; q6mo, every 6 months; q12mo, every 12 months.

**Table 3**

Adjusted mean difference in total femorotibial cartilage thickness with sprifermin 100 µg q6mo ( $n = 34$ ) vs placebo ( $n = 33$ ) in the SAR.

	Number of non-missing values (n)		Adjusted* mean difference with sprifermin 100 µg q6mo vs placebo (95% CI) <sup>†</sup>	Trend test <sup>‡</sup>
	Sprifermin 100 µg q6mo	Placebo		
Year 1	29	29	0.02 (−0.01–0.05)	0.049
Year 1.5	29	26	0.03 (−0.01–0.08)	0.012
Year 2	29	27	0.06 (0.01–0.11)	<0.001
Year 3	25	23	0.05 (−0.01–0.12)	0.002

\* Repeated measure model with adjustment on baseline and pooled country to account for missing data and potential baseline difference generated by the creation of the subgroup and missing data.

<sup>†</sup> CIs are adjusted for multiplicity of treatment groups.

<sup>‡</sup> Dose-effect trend test across all treatment groups for adjusted values from the repeated measure model.

CI, confidence interval; n, number of participants with change from baseline available; q6mo, every 6 months; SAR, subgroup at risk.

symptomatically from increasing cartilage thickness. Conversely, patients whose disease progresses more rapidly may be more likely to exhibit a symptomatic response to treatment [29]. In this post-hoc analysis, we identified a subgroup of patients at risk of structural and symptomatic progression during the trial, based on baseline characteristics.

Although FORWARD met its primary endpoint on structure, there was no differentiation from placebo regarding the key secondary pain outcome. There are several possible reasons for this. Using i.a. saline injections as a control may act as an active placebo [30], masking symptomatic improvements associated with sprifermin. It is well-documented that placebos can yield a clinically relevant response and it is plausible that i.a. saline injections exert effects through the dilution of inflammatory components [31], making it challenging to demonstrate an effect size between placebo and comparator. Furthermore, FORWARD was primarily designed as a dose-finding, structural effects trial, not a pain trial; modern pain inclusion criteria were not implemented. Routine and rescue pain medications were monitored, but not restricted. The ~90% of patients in each treatment group who took additional pain medications in the first 2 years may have contributed to a greater response with placebo.

While mean pain score differences between sprifermin 100 µg and placebo were observed from 1.5 years, the dose-effect trend test did not reach a nominal p-value <0.05 until Year 3 in the SAR. Compared with the cartilage thickness effect, this time lag may have occurred because the pain response was indirect and secondary to structural modification. The delay could reflect a reduction in symptomatic progression due to the structural modification with sprifermin in patients who would otherwise progress more rapidly if left untreated. This underscores the time it takes for structural improvement to translate into a symptomatic benefit, suggesting that it may

not always be measurable within a typical OA clinical trial timeframe in unselected, heterogeneous patient populations. As with the ITT population, a high proportion of SAR placebo-patients demonstrated a WOMAC pain response that was initially comparable to sprifermin.

It is clear that selection of a SAR based on both mJSW and pain criteria was more effective than selection based on either alone, an important message for designers of future trials, although several limitations must be considered. This post-hoc analysis was hypothesis-generating in nature, and results need to be confirmed in independent clinical trials. The SAR had missing data, some baseline imbalances, and small sample sizes with outliers that may have impacted the results. In addition, pain endpoints have large variability. However, sensitivity analyses indicated that the observed mean difference between sprifermin and placebo in WOMAC pain change from baseline was larger than the adjusted mean difference, supporting the main SAR findings. At Year 3, a dose effect trend test gave a nominal p value, <0.05. Finally, it is not known how many patients the medication washout applied to.

## Conclusion

Our findings indicate that, in addition to increasing cartilage thickness, treatment with sprifermin may confer symptomatic benefits, such as decreased pain. This is the first analysis to provide a proof of concept that structure (cartilage thickness) modification in knee OA by an i.a. drug may translate into symptomatic clinical benefit, provided an adequate patient cohort with established disease is selected and followed for a duration long enough to determine potential symptom benefits. Furthermore, this analysis is the first to suggest that enriching a trial population with low mJSW and high WOMAC pain at baseline results in greater differentiation between a

DMOAD and placebo in WOMAC pain. Selecting a more homogenous patient population that is likely to progress within an OA clinical trial timeframe may improve the ability to reach a symptomatic endpoint and ultimately lead to the approval of potential DMOADs. The patient subgroup identified in this analysis may represent a target population for future clinical trials of sprifermin or other potential DMOADs.

### Author contributions

**Hans Guehring:** Data analysis, data interpretation, writing and critical review of the manuscript

**Flavie Moreau:** Biostatistics, data analysis, data interpretation

**Benjamin Daelken:** Writing and critical review of the manuscript

**Christoph Ladel:** Data analysis, data interpretation, writing and critical review of the manuscript

**Oliver Guenther:** Writing and critical review of the manuscript

**Asger Reinstrup Bihlet:** Data analysis, data interpretation, writing of manuscript

**Wolfgang Wirth:** Data interpretation, writing and critical review of the manuscript

**Felix Eckstein:** Data interpretation, writing and critical review of the manuscript

**Marc Hochberg:** Data interpretation, writing and critical review of the manuscript

**Philip G Conaghan:** Analysis design and interpretation, drafting and critical review of manuscript.

### Acknowledgments

The authors would like to thank the FORWARD patients and their families, the study investigators at each participating site, and study committee team members. Medical writing assistance was provided by Emily Heath PhD, Bioscript Stirling Ltd, Macclesfield, UK and supported by Merck KGaA, Darmstadt, Germany, in accordance with Good Publication Practice (GPP3) guidelines (<http://www.ismpp.org/gpp3>). PGC is supported in part by the UK National Institute for Health Research (NIHR) Leeds Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care.

**Presented at:** This work was previously presented at EULAR 2019 (Guehring et al. *Annals of the Rheumatic Diseases* 2019, Volume 78, Issue Suppl 2), DGRh 2019 (Poster number RA.26) and ACR 2019 (Abstract number 2761).

### Funding

The FORWARD study was funded by Merck KGaA, Darmstadt, Germany and EMD Serono Research & Development Institute, Inc; an affiliate of Merck KGaA, Darmstadt, Germany.

### Declaration of Competing Interest

**Hans Guehring** is an employee of Merck KGaA, Darmstadt, Germany

**Flavie Moreau** is an employee of EMD Serono, Billerica, MA, USA; a business of Merck KGaA, Darmstadt, Germany

**Benjamin Daelken** is an employee of Merck KGaA, Darmstadt, Germany

**Christoph Ladel** was an employee of Merck KGaA, Darmstadt, Germany when the work was conducted and is currently an employee of BioBone BV, Amsterdam, Netherlands

**Oliver Guenther** is an employee of Merck KGaA, Darmstadt, Germany

**Asger Reinstrup Bihlet** is an employee and shareholder of Nordic Bioscience Clinical Development (NBCD) A/S, Herlev, Denmark

**Wolfgang Wirth** is an employee and shareholder of Chondrometrics GmbH, Ainring, Germany; he has provided consulting services to Galapagos

**Felix Eckstein** is CEO/CMO and co-owner of Chondrometrics GmbH; he has provided consulting services to Merck KGaA, AbbVie, Samumed, Kolon TissueGene Inc, Servier, Galapagos, Roche, Novartis, ICM, and Healthlink

**Marc Hochberg** reports being the president of Rheumcon Inc and receiving consulting fees from Bone Therapeutics, Bristol-Myers Squibb, Eli Lilly, Galapagos, IBSA Insitutit Biotechniq SA, Novartis Pharma AG, Pfizer, Samumed LLC, Theralogix LLC, and Kolon TissueGene Inc.

**Philip G Conaghan** has done consultancies or speakers bureaus for AbbVie, AstraZeneca, BMS, EMD Serono, a business of Merck KGaA, Darmstadt, Germany, Flexion Therapeutics, Galapagos, Kolon TissueGene Inc, Novartis, Pfizer, Samumed, and Stryker.

### Patient consent for publication

Not required.

### Ethics approval

The study was conducted in accordance with the Declaration of Helsinki, the International Conference on Harmonisation Guidelines for Good Clinical Practice and local regulations. The study protocol [9] and all major amendments were approved by the relevant Institutional Review Boards or Independent Ethics Committees and by Health Authorities, according to country-specific laws.

### Data sharing

Any requests for data by qualified scientific and medical researchers for legitimate research purposes will be subject to Merck KGaA's Data Sharing Policy. All requests should be submitted in writing to Merck KGaA's data sharing portal. When Merck KGaA has a co-research, co-development, or co-marketing or co-promotion agreement, or when the product has been out-licensed, the responsibility for disclosure might be dependent on the agreement between parties. Under these circumstances, Merck KGaA will endeavour to gain agreement to share data in response to requests.

### Supplementary materials

Supplementary material associated with this article can be found, in the online version, at doi:[10.1016/j.semarthrit.2021.03.005](https://doi.org/10.1016/j.semarthrit.2021.03.005).

### References

- [1] Hunter D, Bierma-Zeinstra S. Osteoarthritis. *Lancet* 2019;393(10182):1745–59.
- [2] Martel-Pelletier J, Barr AJ, Cicuttini FM, Conaghan PG, Cooper C, Goldring MB, et al. Osteoarthritis. *Nat Rev Dis Primers* 2016;2:16072.
- [3] Hermann W, Lambova S, Muller-Ladner U. Current treatment options for osteoarthritis. *Curr Rheumatol Rev* 2018;14(2):108–16.
- [4] Gregori D, Giacobelli G, Minto C, Barbeta B, Gualtieri F, Azzolina D, et al. Association of pharmacological treatments with long-term pain control in patients with knee osteoarthritis: a systematic review and meta-analysis. *JAMA* 2018;320(24):2564–79.
- [5] Charlesworth J, Fitzpatrick J, Perera N, Orchard J. Osteoarthritis - a systematic review of long-term safety implications for osteoarthritis of the knee. *BMC Musculoskelet Disord* 2019;20(1):151.
- [6] Barr A, Conaghan P. Disease-modifying osteoarthritis drugs (DMOADs): what are they and what can we expect from them? *Medicographia* 2013;35:189–96.
- [7] Karsdal M, Michaelis M, Ladel C, Siebuhr A, Bihlet A, Andersen J, et al. Disease-modifying treatments for osteoarthritis (DMOADs) of the knee and hip: lessons learned from failures and opportunities for the future. *Osteoarthr Cartil* 2016;24(12):2013–21.
- [8] Oo W, Yu S, Daniel M, Hunter D. Disease-modifying drugs in osteoarthritis: current understanding and future therapeutics. *Expert Opin Emerg Drugs* 2018;23(4):331–47.

- [9] Gigout A, Guehring H, Froemel D, Meurer A, Ladel C, Reker D, et al. Sprifermin (rhFGF18) enables proliferation of chondrocytes producing a hyaline cartilage matrix. *Osteoarthr Cartil* 2017;25(11):1858–67.
- [10] Reker D, Kjelgaard-Petersen CF, Siebuhr AS, Michaelis M, Gigout A, Karsdal MA, et al. Sprifermin (rhFGF18) modulates extracellular matrix turnover in cartilage explants ex vivo. *J Transl Med* 2017;15(1):250.
- [11] Sennett ML, Meloni GR, Farran AJE, Guehring H, Mauck RL, Dodge GR. Sprifermin treatment enhances cartilage integration in an in vitro repair model. *J Orthop Res* 2018;36(10):2648–56.
- [12] Moore EE, Bendele AM, Thompson DL, Littau A, Waggle KS, Reardon B, et al. Fibroblast growth factor-18 stimulates chondrogenesis and cartilage repair in a rat model of injury-induced osteoarthritis. *Osteoarthr Cartil* 2005;13(7):623–31.
- [13] Hochberg M, Guermazi A, Guehring H, Aydemir A, Wax S, Fleuranceau-Morel P, et al. Effect of intra-articular sprifermin vs placebo on femorotibial joint cartilage thickness in patients with osteoarthritis: the FORWARD randomized clinical trial. *JAMA* 2019;322(14):1360–70.
- [14] Deveza L, Downie A, Tamez-Peña J, Eckstein F, Van Spil W, Hunter D. Trajectories of femorotibial cartilage thickness among persons with or at risk of knee osteoarthritis: development of a prediction model to identify progressors. *Osteoarthr Cartil* 2019;27(2):257–65.
- [15] Eckstein F, Collins J, Nevitt M, Lynch J, Kraus V, Katz J, et al. Cartilage thickness change as an imaging biomarker of knee osteoarthritis progression: data from the foundation for the national institutes of health osteoarthritis biomarkers consortium. *Arthritis Rheumatol* 2015;67(12):3184–9.
- [16] Kwok C, Ran D, Ashbeck E, Duryea J. Distinct trajectories of medial fixed joint space width loss over four years of follow-up among knees with and at risk for knee osteoarthritis [ACR/ARHP annual meeting abstract]. *Arthritis Rheumatol* 2017;69:2948. abstract.
- [17] Bowes M, Guillard G, Brett A, Vincent G, Conaghan P. Optimizing recruitment criteria for an osteoarthritis structure modification trial: data from the oai [EULAR 2017 abstract]. *Ann Rheum Dis* 2017;76:119–20.
- [18] Wirth W, Nevitt M, Hellio Le Graverand M, Lynch J, Maschek S, Hudelmaier M, et al. Lateral and medial joint space narrowing predict subsequent cartilage loss in the narrowed, but not in the non-narrowed femorotibial compartment—data from the Osteoarthritis Initiative. *Osteoarthr Cartil* 2014;22(1):63–70.
- [19] Maschek S, Wirth W, Ladel C, Hellio Le Graverand M, Eckstein F. Rates and sensitivity of knee cartilage thickness loss in specific central reading radiographic strata from the osteoarthritis initiative. *Osteoarthr Cartil* 2014;22(10):1550–3.
- [20] Eckstein F, Cotofana S, Wirth W, Nevitt M, John M, Dreher D, et al. Greater rates of cartilage loss in painful knees than in pain-free knees after adjustment for radiographic disease stage: data from the osteoarthritis initiative. *Arthritis Rheumatol* 2011;63(8):2257–67.
- [21] Krupka E, Jiang G, Jan C. Efficacy and safety of intra-articular injection of tropomyosin receptor kinase a inhibitor in painful knee osteoarthritis: a randomized, double-blind and placebo-controlled study. *Osteoarthr Cartil* 2019;27(11):1599–607.
- [22] Kwok C, Guehring H, Aydemir A, Hannon M, Eckstein F, Hochberg M. Predicting knee replacement in participants eligible for disease-modifying osteoarthritis drug treatment with structural endpoints. *Osteoarthr Cartil* 2020;28(6):782–91.
- [23] Widera P, Welsing P, Ladel C, Loughlin J, Lafeber F, Petit Dop F, et al. Multi-classifier prediction of knee osteoarthritis progression from incomplete imbalanced longitudinal data. *Sci Rep* 2020;10(1):8427.
- [24] Bellamy N, Hochberg M, Tubach F, Martin-Mola E, Awada H, Bombardier C, et al. Development of multinational definitions of minimal clinically important improvement and patient acceptable symptomatic state in osteoarthritis. *Arthritis Care Res (Hoboken)* 2015;67(7):972–80.
- [25] Katz J, Neogi T, Callahan L, Block J, Conaghan P, Simon L, et al. Disease-modifying effects of a novel cathepsin K inhibitor in osteoarthritis: a randomized, placebo-controlled study. *Ann Intern Med* 2019 Epub ahead of print 31 December 2019.
- [26] Helliö le Graverand M, Clemmer R, Redifer P, Brunell R, Hayes C, Brandt K, et al. A 2-year randomised, double-blind, placebo-controlled, multicentre study of oral selective iNOS inhibitor, cindunistat (SD-6010), in patients with symptomatic osteoarthritis of the knee. *Ann Rheum Dis* 2013;72(2):187–95.
- [27] Eckstein F, Kraines J, Aydemir A, Wirth W, Maschek S, Hochberg M. Intra-articular sprifermin reduces cartilage loss in addition to increasing cartilage gain independent of location in the femorotibial joint: post-hoc analysis of a randomised, placebo-controlled phase II clinical trial. *Ann Rheum Dis* 2020;79(4):525–8.
- [28] Conaghan P, Kloppenburg M, Schett G, Bijlsma J. Osteoarthritis research priorities: a report from a EULAR ad hoc expert committee. *Ann Rheum Dis* 2014;73(8):1442–5.
- [29] Saltzman B, Leroux T, Meyer M, Basques B, Chahal J, Bach BJ, et al. The therapeutic effect of intra-articular normal saline injections for knee osteoarthritis: a meta-analysis of evidence level 1 studies. *Am J Sports Med* 2017;45(11):2647–53.
- [30] Bannuru R, McAlindon T, Sullivan M, Wong J, Kent D, Schmid C. Effectiveness and implications of alternative placebo treatments: a systematic review and network meta-analysis of osteoarthritis trials. *Ann Intern Med* 2015;163(5):365–72.